View in EDS

Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations.

Saved in:
Bibliographic Details
Title: Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations.
Authors: Mayhew D; Computational Biology, Target Sciences, GSK R&D, King of Prussia, Pennsylvania, USA., Devos N; GSK Vaccines, Rixensart, Belgium., Lambert C; GSK Vaccines, Rixensart, Belgium., Brown JR; Computational Biology, Target Sciences, GSK R&D, King of Prussia, Pennsylvania, USA., Clarke SC; Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, UK.; Southampton NIHR Respiratory Biomedical Research Unit, Southampton General Hospital, Southampton, UK., Kim VL; Southampton NIHR Respiratory Biomedical Research Unit, Southampton General Hospital, Southampton, UK., Magid-Slav M; Computational Biology, Target Sciences, GSK R&D, King of Prussia, Pennsylvania, USA., Miller BE; Respiratory Therapy Area Unit, GSK R&D, King of Prussia, Pennsylvania, USA., Ostridge KK; Southampton NIHR Respiratory Biomedical Research Unit, Southampton General Hospital, Southampton, UK., Patel R; Target and Pathway Validation, Target Sciences, GSK R&D, King of Prussia, Pennsylvania, USA., Sathe G; Target and Pathway Validation, Target Sciences, GSK R&D, King of Prussia, Pennsylvania, USA., Simola DF; Computational Biology, Target Sciences, GSK R&D, King of Prussia, Pennsylvania, USA., Staples KJ; Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, UK.; Southampton NIHR Respiratory Biomedical Research Unit, Southampton General Hospital, Southampton, UK.; Wessex Investigational Sciences Hub, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, UK., Sung R; Respiratory Therapy Area Unit, GSK R&D, King of Prussia, Pennsylvania, USA., Tal-Singer R; Respiratory Therapy Area Unit, GSK R&D, King of Prussia, Pennsylvania, USA., Tuck AC; Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, UK., Van Horn S; Target and Pathway Validation, Target Sciences, GSK R&D, King of Prussia, Pennsylvania, USA., Weynants V; GSK Vaccines, Rixensart, Belgium., Williams NP; Southampton NIHR Respiratory Biomedical Research Unit, Southampton General Hospital, Southampton, UK., Devaster JM; GSK Vaccines, Rixensart, Belgium., Wilkinson TMA; Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, UK.; Southampton NIHR Respiratory Biomedical Research Unit, Southampton General Hospital, Southampton, UK.; Wessex Investigational Sciences Hub, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, UK.
Corporate Authors: AERIS Study Group
Source: Thorax [Thorax] 2018 May; Vol. 73 (5), pp. 422-430. Date of Electronic Publication: 2018 Jan 31.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: British Medical Assn Country of Publication: England NLM ID: 0417353 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3296 (Electronic) Linking ISSN: 00406376 NLM ISO Abbreviation: Thorax Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1468-3296
DOI:10.1136/thoraxjnl-2017-210408